Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and dexamethasone before donor lymphocyte infusion for relapsed or progressive multiple myeloma after allogeneic transplantation
2006-004815-24Phase 2Terminated
- Sponsor
- Michelangelo Foundation
- Start
- Apr 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib and dexamethasone in multiple myeloma (MM), sponsored by Michelangelo Foundation. Primary endpoint: Number of stringent clinical complete remission, complete remission and partial remission. Started Apr 2007; status: terminated.
02
Drugs
bortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2006-004815-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004815-24.